Press Release Biotechnology 1 min read

Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development

Allink Biotherapeutics raised $47 million in Series A extension rounds led by Legend Capital and Meituan Long-Z Investment to advance its clinical-stage ADC and multi-specific antibody programs for oncology and immunology.

Lanchi Ventures Yuanbio Venture Capital 5Y Capital Lapam Capital Runzhang Venture Capital Allink Biotherapeutics Inc.
Press ReleaseDecember 16, 2025
Lanchi Ventures

Allink Biotherapeutics raised $47 million in Series A extension rounds led by Legend Capital and Meituan Long-Z Investment to advance its clinical-stage ADC and multi-specific antibody programs for oncology and immunology.

Related articles

Press ReleaseMay 8, 2026
West Enclave Merger Corp.

West Enclave Merger Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing May 13, 2026

May 8, 2026
Press ReleaseMay 8, 2026
Shreya Acquisition Group

Shreya Acquisition Group Announces Closing of $110 Million Initial Public Offering (Including Partial Exercise of Over-Allotment Option)

May 8, 2026
Press ReleaseMay 8, 2026
Consolidated Edison

Con Edison Announces $2 Billion At-The-Market (ATM) Equity Offering Program

May 8, 2026
← Back to all articles

Generated by Yeal